文档下载 文档下载导航
设为首页 | 加入收藏
搜索 请输入内容:  
 导航当前位置: 文档下载 > 所有分类 > 医药卫生 > 呼吸道合胞病毒单克隆抗体使用说明书
侵权投诉

呼吸道合胞病毒单克隆抗体使用说明书

呼吸道合胞病毒单克隆抗体使用说明书

Injectable Medication Guideline:

Synagis (Palivizumab)

CCS Guidelines for the Authorization of Synagis:

Infants and children must meet above criteria in addition to meeting the following CCS criteria:

Infant or child must have a CCS-eligible condition

The request for Synagis shall be made by the CCS authorized pediatric subspecialist or the CCS

approved Special Care Center; or the request shall be made by a CCS-paneled pediatrician authorized in conjunction with a CCS paneled pediatric subspecialist or CCS approved Special Care Center

Premature infants who are currently eligible only for diagnostic services through the high-risk

infant follow-up program are not eligible for CCS authorization of palivizumab

Synagis Dosing:

15mg/kg to be administered intramuscularly once a month

Note: Providers may bill for one vial of Synagis even if only part of the vial was given to the recipient and the remainder of the drug was discarded. However, the provider may not bill for the 100 mg vial when the dose required for the recipient is than 50 mg.

Cost (AWP as of December 2011):

Synagis (palivizumab) 50mg vial (each) = $1,915

Synagis (palivizumab) 100mg vial (each) = $2,675

REFERENCES

1. American Academy of Pediatrics. Summaries of Infectious Diseases, Repiratory Syncytial Virus. Red

Book 2009.

2. Meissner HC and Bocchini JA. Reducing RSV hospitalizations. AAP modifies recommendations for

use of palivizumab in high-risk infants, young children. American Academy of Pediatrics News. July 2009. Volume 30 (7):1-2.

3. American Academy of Pediatrics, Subcommittee on Diagnosis and Management of Bronchiolitis.

Diagnosis and management of bronchiolitis. Pediatrics. 2006;116 (4): 1774-1793.

4. American Academy of Pediatrics, Committee on Infectious Diseases and Committee on Fetus and

Newborn. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. Pediatrics. 1998;102(5):1211-16.

5. Meissner HC, et al. Prevention of respiratory syncytial virus infection in high risk infants: consensus

opinion on the role of immunoprophylaxis with respiratory syncytial virus hyperimmune globulin. Pediatr Infect Dis J. 1996;15(12):1059-68.

6. The Impact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal

antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1996;97:137-140.

7. California Department of Health Care Services. Palivizumab (Synagis). N.L. 04-0509, August 2009.

8. Sondheimer HM, Cabalka AK, Feltes TF, Piazza FM, Conner EM, and the Cardiac Synagis Study

Group. Palivizumab (PV) prevents hospitalization due to respiratory syncytial virus (RSV) in young children with serious congenital heart disease (CHD). Protocol CP048. Presented at the Cardiology Section of American Academy of Pediatrics Conference, Oct.18, 2002. Data on file, MedImmune, Inc.

9. Romero JR. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results

from four years of palivizumab usage. Pediatr Infect Dis J. 2003;22(2):S46-S54.

10. Holman RC, et al. Risk factors for bronchiolitis-associated deaths among infants in the United States.

Pediatr Infect Dis J. 2003;22(6):483-489.

11. Synagis Product Information. MedImmune. March 2009. Gaithersburg, MD.

上一页第2页

你可能喜欢

热门文档

相关文档

站点地图 | 文档上传 | 侵权投诉 | 手机版
本站所有资源均来自互联网,本站只负责收集和整理,均不承担任何法律责任,如有侵权等其它行为请联系我们.
文档下载 Copyright 2013 doc.guandang.net All Rights Reserved.  -  email